China obesity biotech QL Biopharm gets $72M, including support from OrbiMed

Positive

AI Analysis

Summary

QL Biopharm, a late-stage Chinese obesity biotech, raised $72 million in Series C funding led by OrbiMed and Qiming Venture Partners. The funding supports development in the competitive obesity drug market.

Outcome Details

Series C funding round

Importance:6/10

Sentiment:

0.60

obesityChinaSeries C fundinglate-stage biotechventure capital

Related Companies

$CFOO

Read the original article

Published by Endpoints News on March 2, 2026 12:14 PM

Read Original